Site of Recurrence in Patients. of the Lung Resected for Cure. with Stages I and I1 Carcinoma
|
|
- Lynne Weaver
- 5 years ago
- Views:
Transcription
1 Site of Recurrence in Patients with Stages I and I1 Carcinoma of the Lung Resected for Cure Steven C. Immerman, M.D., Robert M. Vanecko, M.D., Willard A. Fry, M.D., Louis R. Head, M.D., and Thomas W. Shields, M.D. ABSTRACT Ninety-nine patients with Stage I or 11 lung carcinoma that was other than the small cell type and who survived for more than 30 days after a "curative" resection were followed for five years or until death if it occurred prior to the five-year anniversary. Recurrent disease developed in 44 patients. Clinical data and data from postmortem examination were reviewed in these 44 patients in an attempt to classify each recurrence as either initially local or distant metastatic disease. The site of the first documented recurrence was local in 18 patients and distant metastases in 26. When the patients with recurrence were separated into TNM categories, it was apparent that in those patients without lymph node metastases demonstrated in the resected specimen (NO), the initial recurrence tended to be a distant metastases, whereas in those with such involvement (Nl), the initial occurrence was more often local. In light of these data, selection of appropriate initial adjuvant therapeutic modalities may be different for each type of patient. Surgical resection is the therapy of choice in patients with Stage I or Stage I1 carcinoma of the lung that is other than the small cell type. These stages include those patients whose disease may be categorized pathologically as T1 NO, T1 N1, T2 NO, and T2 N1. All patients in these two stages are assumed to have no distant metastasis (MO). However, despite the apparent removal of all local disease, local recurrence or distant metastases will develop within five years in a large number of such patients. In order to determine the incidence and the initial From the Department of Surgery, Northwestern University Medical School, Chicago, IL. Presented at the Seventeenth Annual Meeting of The Society of Thoracic Surgeons, Jan 26-28,1981, Los Angeles, CA. Address reprint requests to Dr. Shields, Department of Surgery, Northwestern University Medical School, 303 E Chicago Ave, Chicago, IL site of recurrence in Stage I and Stage I1 patients, we reviewed the records of a series of patients whose disease was classified as T1 NO, T2 NO, T1 N1, or T2 N1, who had undergone curative resection (no microscopic proof of residual disease remaining in the ipsilateral hemithorax), and who were eligible for fiveyear survival. It is believed that the evaluation of this information may make it possible to better determine the most appropriate initial adjuvant therapeutic modality for each TN category in these Stage I and Stage I1 groups. Material and Methods The hospital charts, office records, and postmortem reports for all patients with pathological Stage I or Stage I1 carcinoma of the lung that was not of the small cell type and that was resected for cure from 1967 through 1975 were reviewed. Three of the teaching hospitals of Northwestern University Medical School were involved in this review: Northwestern Memorial Hospital, Veterans Administration Lakeside Medical Center, and Evanston Hospital. One hundred twenty-two patients in these two categories who had undergone resection were found. Three died within 30 days of the operation, and 20 were lost to follow-up; these 23 patients were excluded from the study. Complete data were obtained on the other 99 patients. All were followed for five years or until death if it occurred before the fifth year anniversary. The presence or absence of tumor at the time of death or at the fifth anniversary of each patient was determined. In addition, specific attention was paid to the initial site of recurrence. Local recurrence was defined as any recurrent disease within the ipsilateral hemithorax, ipsilateral supraclavicular lymph nodes, or mediastinum. All other sites of recurrence were considered distant metastases by The Society of Thoracic Surgeons
2 24 The Annals of Thoracic Surgery Vol 32 No 1 July 1981 Only biopsy-proved recurrence or histologically confirmed postmortem findings were considered in these determinations. Results There were 72 men and 27 women. Each patient was assigned a specific TN category from review of the pathological report of the resected specimen. Thirty-nine patients were judged to have T1 NO disease (a lesion no greater than 3 cm in size at or distal to a lobar bronchus and no visceral pleural involvement; all lymph node groups free from metastatic disease). Thirtyeight patients had T2 NO disease (a lesion greater than 3 cm in size at least 2 cm distal to the tracheal carina, or a tumor of any size with visceral pleural involvement; no metastatic involvement of any lymph node group). There were 4 patients with T1 N1 disease and 18 with T2 N1 disease (similar T1 or T2 designations, but with metastatic disease in either the lobar or hilar lymph nodes; mediastinal nodes free from disease). The last two categories were combined since the prognosis has been shown to be similar in both groups [l, 21. The histological diagnosis was squamous cell carcinoma in 43 patients, adenocarcinoma in 34, and undifferentiated large cell carcinoma in 17. Five patients were classified as having mixed adenosquamous cell carcinoma. Forty-nine patients were alive at the fifth year anniversary, a 49% five-year survival. Four of these patients had documented recurrent disease prior to this fifth anniversary. Thus, the overall five-year disease-free survival was 45%. In the patients with T1 NO disease, the five-year disease-free survival was 64%; in those with T2 NO disease, it was 45%; and in those patients in the combined group of T1 N1 and T2 N1, it was 14% (Table 1). Fifty patients had died before the fifth anniversary, 10 of them without clinical or postmortem evidence of recurrent carcinoma. Forty patients died with recurrent disease either biopsy-proved or demonstrated at postmortem examination. Thus of the 99 patients, 44 (44%) were treatment failures. The site of the first documented recurrence was a local recurrence in 18 patients and a distant metastasis in 26. Seven of these patients either manifested recurrence clinically or were discovered at postmortem examination to have both local recurrence and distant metastases. Distant metastases were recognized somewhat earlier than local recurrence, but not by a substantial period of time. In 55% of the patients, the recurrent disease was noted within the first year of operation and in 80% by the second anniversary. Of the 4 patients who were alive with recurrent disease at the fifth anniversary, recurrence in 1 developed during the second year and apparently was successfully treated by irradiation. In a second patient, the recurrent disease was noted in the fourth postoperative year; he remains alive with disease three years later. In the other 2 patients, the recurrent disease occurred in the first and fourth years; both died of the disease after the fifth year. In all 4 patients, the cell type was adenocarcinoma. When the patients with recurrent disease were separated into the Tl NO, T2 NO, and T1 N1 plus T2 N1 categories, either local or distant recurrence was observed in 11 of 39 patients (28O/0), 19 of 38 patients (50%), and 14 of 22 patients (64%), respectively. Initial local recurrence or distant metastasis was noted with equal frequency in the T1 NO patients. Initial distant Table 1, Survival Related to TNM Classification Patients Alive at 5 Years Patients Dead TNM No. of No No Status Patients Disease Disease Disease Disease T1 NO (64%) 9 3 T2 NO (45%) 17 2 T1 N1 + T2 N (14%) 14 5 Total 99 4 (4%) 45 (45%) 40 (40%) 10 (10%)
3 25 Immerman et al: Site of Recurrence in Stages I and I1 Carcinoma of the Lung Table 2. Site of First Recurrence Related to TNM Sfatus TNM No. of Local Distant Total Status Patients Recurrence Metastasis Recurrence T1 NO 39 5 (13%) 6 (15%) 11 (28%) T2 NO 38 4 (10.5%) 15 (39.5%) 19 (50%) T1 N1 + T2 N (41%) 5 (23%) 14 (64%) Total (18%) 26 (26%) 44 (44%) Table 3. Frequency of Recurrence Related to Cell Type Cell Type No. of No Patients Recurrence Recurrence Squamous (35%) 28 (65%) Adenocarcinoma (53%) 16 (47%) Large cell 17 7 (41%) 10 (59%) Mixed adeno- 5 4 (80%) 1(20%) squamous Total (44%) 55 (56%) metastases was evident four times more often than initial local recurrence in patients with T2 NO lesions. The patients with T1 N1 and T2 N1 lesions were found to have initial local recurrence twice as commonly as distant metastases (Table 2). In this series it was apparent that there was a tendency for the T1 N1 and T2 N1 lesions to recur locally and for the T2 NO lesions to manifest distant metastases. The 38 patients with T2 NO lesions had a 39.5% rate of distant recurrence and the 22 patients with either T1 N1 or T2 N1 lesions had a 41% rate of local recurrence. That the T2 NO lesions recur distantly and T1 N1 and T2 N1 lesions recur locally is significant at the p < level. When the patients were analyzed with respect to cell type, without regard to TN category, the patient with squamous cell carcinoma had the lowest rate of recurrence compared with the other two cell types (Table 3). However, cell type did not appear to have an influence on the initial site or time of recurrence. Comment The results of curative resection for carcinoma of the lung depend primarily on the stage of the disease at the time of operation. Although numerous factors relative to the patient and the disease are known to affect the prognosis, the size of the tumor and the presence or absence of lymph node metastases seem to be the more important factors [3-51. The specific cell type is of less consequence in tumors that are not of the small cell type [5]. Since surgical resection fails to cure all patients in whom the local disease has been excised, future improvement will be due to refinement of adjuvant therapeutic maneuvers. However, adjuvant therapy, except in isolated reports such as those of McKneally [6], Kirsh [7], and their associates, as well as others [8, 91, has not proved to be of great benefit in surgically treated patients with carcinoma of the lung [lo, 113. Nonetheless, if the site at which the tumor is most likely to recur in the various patient groups can be predicted, prophylactic adjuvant therapy may be used more accurately. Few data are available relative to the initial site of recurrence in successfully resected patients with Stage I or Stage I1 carcinoma of the lung. The autopsy data of Matthews and associates [12, 131 and of Rocmans' for patients dying within thirty days of operation are not too helpful except to note that in the presence of lymph node metastasis, recurrent or persistent disease in the hemithorax was more common than occult distant metastases. In a similar but smaller series, Mountain and Hermes [141 found initial distant metastasis to be more common than initial local recurrence in patients with either Stage I or Stage I1 disease. However, in our group of patients, the initial site of recurrence was more often a distant metastasis in patients without lymph node metastasis and a *Rocmans P: Personal communication, 1980.
4 26 The Annals of Thoracic Surgery Vol 32 No 1 July 1981 local recurrence in those with lymph node metastasis in the resected specimen. Evaluation of our results suggest that the primary adjuvant therapeutic modality for patients without lymph node metastases should be systemic adjuvant therapy; that is, either chemotherapy or immunotherapy. In the patients with tumor metastasis in either the lobar or hilar lymph nodes, the incidence of local recurrence is high and it seems reasonable that adjuvant therapy should be directed to local control. At present, radiation therapy would appear to be the therapeutic modality of choice for this latter group of patients. References 1. Shields TW, Keehn RJ: Postresection stage grouping in carcinoma of the lung. Surg Gynecol Obstet 145: , Shields TW, Humphrey EW, Easteridge CE, et al: Pathologic stage grouping of the patients with resected carcinoma of the lung. J Thorac Cardiovasc Surg 80: , Higgins GA, Shields TW, Keehn RJ: The solitary pulmonary nodule: ten-year follow-up of Veterans Administration-Armed Forced Cooperative Study. Arch Surg 110: , Soorae AS, Abbey-Smith R: Tumor size as a prognosis factor after resection of lung carcinoma. Thorax 32:19-25, Shields TW, Yee J, Conn JH, Robinette CD: Relationship of cell type and lymph node metastasis to survival after resection of bronchial carcinoma. Ann Thorac Surg 20: , McKneally MF, Maver CM, Alley RD, et al: Regional immunotherapy of lung cancer using intrapleural BCG: summary of a four year randomized study. In Muggia F, Rozencweig M (eds): Lung Cancer: Progress in Therapeutic Research. New York, Raven Press, Kirsh MM, Rotman H, Argenta L, et al: Carcinoma of the lung: results of treatment over ten years. Ann Thorac Surg 21: , Green N, Kurohara SS, George FW 111, Crews QE Jr: Postresection irradiation for primary lung cancer. Radiology 116:405, Martini N, Flehinger BJ, Saman MB, Beattie EJ Jr: Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg 80: , Higgins GA Jr, Shields TW: Experience of the Veterans Administration Surgical Adjuvant Group. In Muggia F, Rozencweig M (eds): Lung Cancer: Progress in Therapeutic Research. New York, Raven Press, , Shields TW: Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer 30~ , Matthews MJ, Kanhouwa S, Pickren J, Robinette D: Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep 4:63-67, Matthews MJ, Pickren J, Kanhouwa S: Who has occult metastases? Residual tumor in patients undergoing surgical resections for lung cancer. In Williams TE Jr, Wilson HE, Yohn DS (eds): Perspectives in Lung Cancer: Proceedings of the Frederick E. Jones Memorial Symposium in Thoracic Surgery, Columbus, OH, Karger, Basel, 1977, pp Mountain CR, Hermes KE: Management implications of surgical staging studies. In Muggia F, Rozencweig M (eds): Lung Cancer: Progress in Therapeutic Research, New York, Raven Press, 1979, pp Discussion DR. PETER c. PAIROLERO (Rochester, MN): I congratulate Dr. Immerman on this timely discussion of recurrent lung cancer. All of us who utilize the TNM classification appreciate these data, and hope that this system will eventually enable us to compare results more confidently. To better interpret Dr. Immerman s data, however, we need to know more about his patient population. For instance, how many patients with lung cancer did his group evaluate during the study? Did his 122 eligible patients include all patients with Stage I disease after surgical treatment? Perhaps Dr. Immerman also could elaborate further on which patients were ineligible. For instance, would a patient who is not likely to survive five years be considered ineligible? Finally, how does a 17% loss of follow-up information influence their data? Our experience with 350 patients with Stage I lung cancer after operation demonstrates a five-year survival of 71%. There has been recurrence in one-third of these patients, or 116. The rate of recurrence, however, varies with the different TN subgroups. The patients with T1 NO lesions have a 27% recurrence; those with T2 NO lesions, 37%; and those with T1 N1 lesions, 58%. Only the recurrence in the patients with T2 NO lesions differs from Dr. Immerman s study: they demonstrated a 53% recurrence. I ask Dr. Immerman to tell us to what extent mediastinal lymph nodes were actually biopsied in their patient population. If the nodes were not uniformly biopsied, it may be possible that some patients had an occult N2 lesion, which ultimately led to an increase in the recurrence rate. We utilize a different classification of recurrent lung cancer. In addition to regional occurrences and metastases, we include a third category of sub-
5 27 Immerman et al: Site of Recurrence in Stages I and I1 Carcinoma of the Lung sequent primary lung cancer. Approximately half of our recurrences are metastatic, one-fourth are regional, and one-fourth involve a new second primary lung cancer. If these recurrences are analyzed according to both their TN classification and their specific type, metastases continues to account for approximately half of the recurrences in each of the three subgroups of Stage I. We do not approach the one to four ratio of regional to metastatic recurrences that Dr. Immerman described in patients with T2 NO lesions, unless we group together second primary cancers and metastatic cancers. Dr. Immerman, what is your opinion regarding the possibility of a second primary lung cancer? Specifically, how should a patient with a resected squamous cell carcinoma of the right upper lobe who returns three years later with a solitary adenocarcinoma of the left lower lobe be classified? DR. ROBERT J. GINSBERG (Toronto, Ont, Canada): I congratulate Dr. Immerman on addressing the problem of the first site of recurrence, using the TNM classification of lung cancer. Only through such detailed staging will we be able to determine what types of adjuvant therapy may be indicated in the various stages of lung cancer following surgical treatment. The Lung Cancer Study Group of the National Institutes of Health has now evaluated 650 patients. We have mapped in detail the mediastinal nodes at thoracotomy prior to resection. In our group with NO lesions, we have found, like Dr. Immerman, that many had distant metastases. However, one-third of all first recurrences were seen in the brain, the commonest single site of first recurrence. Obviously the suggestion that adjuvant chemotherapy in this group of patients might be beneficial is negated by the fact that a third recur in a relatively chemotherapyresistant area-the brain. The other thing we have noted is that many of the patients suspected to have T2 N1 lesions really have T2 N2 lesions when lymph node mapping of the mediastinum is done. I m not sure this was done in Dr. Immerman s series. In our N1 and N2 groups, we have found that at least as many had recurrence distantly as locally. We have already identified 40 local recurrences and 48 distant recurrences. Therefore, radiotherapy alone might not play as big a part as one might think in preventing recurrent disease. In our experience more than half of the recurrences initially occur distantly, outside the field of radiotherapy treatment. DR. SHIELDS: I thank the discussants for their remarks. I always find it quite difficult to answer all their questions, especially since they have had several weeks to think about their questions while I have but two minutes to rebut them. There is no question that in this series a number of patients may well have been understaged. Most of the patients were done before the birth of the staging system. I think we are all well aware now that we should map the mediastinum and thereby stage our patients more appropriately. Nonetheless, I think it does show that even though the numbers are different, there is a similarity in the categories of recurrences. One of the differences that can occur in T2 NO lesions is the size of the lesion. If it is 3 to 5 cm, the patient has a reasonably good chance of survival. If it is 5 to 7 cm or larger, the patient has a much smaller chance of survival and such patients do have a high incidence of distant metastases. I think this may explain some of the difference between the Mayo group and our group with respect to the incidence of recurrence. Certainly, the patients with lymph nodes involved in the hilar and lobar area do not do well. Perhaps this is the group that should have received irradiation, and perhaps this will take care of the micrometastases left behind in the mediastinum. We purposely picked only the patients with Stage I and Stage I1 disease. Once you have a documented N2 lesion, the patient is in Stage I11 and we know that these patients without adjuvant therapy do very poorly. At the moment we have no good adjuvant for T1 NO lesions. These patients do pretty well without adjuvant therapy; only 28% have recurrent disease. This might well be the place for immunotherapy if we find the right modality to take care of the micrometastases that may be present. In the patients with a T2 NO lesion, certainly the chemotherapeutic regimens we have used to date have been inappropriate. We must be careful that when we do use one, it won t actually harm the patient. In line with the comment of Dr. Ginsberg, there is a high incidence of cerebral metastases in these patients. It is our impression that a fair number of these patients have adenocarcinoma originally classified as T1 NO and T2 NO. Perhaps prophylactic brain irradiation might be indicated in this specific group of patients, though we do not have data to support that at this time. Certainly we do not know what wholebrain irradiation would do to patients who survive over a prolonged period.
P sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationTumour size as a prognostic factor after resection of lung carcinoma
Tumour size as a prognostic factor after resection of lung carcinoma A. S. SOORAE AND R. ABBEY SMITH Thorax, 1977, 32, 19-25 From the Cardio-Thoracic Unit, Walsgrave Hospital, Clifford Bridge Road, Coventry
More informationThe Role of Radiation Therapy
The Role of Radiation Therapy and Surgery in the Treatment of Bronchogenic Carcinoma R Adams Cowley, M.D., Morris J. Wizenberg, M.D., and Eugene J. Linberg, M.D. A study of the combined use of preoperative
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationof Surgery for Control of Lung Cancer
Assessment of the Role of Surgery for Control of Lung Cancer Clifton F. Mountain, M.D. ABSTRACT When morphologically stratified, the classification of patients according to surgical stage provides an objective
More informationSignificance of Metastatic Disease
Significance of Metastatic Disease in Subaortic Lymph Nodes G. A. Patterson, M.D., D. Piazza, M.D., F. G. Pearson, M.D., T. R. J. Todd, M.D., R. J. Ginsberg, M.D., M. Goldberg, M.D., P. Waters, M.D., D.
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationThe Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationPrognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer
Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,
More informationChemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma
Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma of the Lung Scott L. Faulkner, M.D., R. Benton Adkins, Jr., M.D., and Vernon H. Reynolds, M.D. ABSTRACT Ten patients with inoperable or recurrent
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationCauses of Treatment Failure and Death in Carcinoma of the Lung
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 54 (1981), 201-207 Causes of Treatment Failure and Death in Carcinoma of the Lung JAMES D. COX, M.D.,a AND RAYMOND A. YESNER, M.D.b The Medical College of Wisconsin,
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationNeedle Biopsy. Transcarinal Bronchoscopic. Robert T. Fox, M.D., William M. Lees, M.D., + and Thomas W. Shields, M.D.I
Transcarinal Bronchoscopic Needle Biopsy Robert T. Fox, M.D., William M. Lees, M.D., + and Thomas W. Shields, M.D.I B KONCHOSCOPIC EXAMINATION has for years been one of the major aids in diagnosis and
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationSURVIVAL AFTER LUNG RESECTION FOR BRONCHIAL CARCINOMA
Thorax (1955), 10, 183. SURVIVAL AFTER LUNG RESECTION FOR BRONCHIAL CARCINOMA BY J. R. BIGNALL AND A. J. MOON From the Brompton Hospital, the London Chest Hospital, and the Institute of Diseases of the
More informationNon-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital
Non-Small Cell Lung Cancer: Disease Spectrum and Management in a Tertiary Care Hospital Muhammad Rizwan Khan,Sulaiman B. Hasan,Shahid A. Sami ( Department of Surgery, The Aga Khan University Hospital,
More informationTreatment of Inoperable Lung Carcinoma: A Combined Modality Approach
Treatment of Inoperable ung Carcinoma: A Combined Modality Approach Hiroshi Takita, M.D., Ariel C. Hollinshead, h.d., Donna J. Rizzo, R.N., Christine M. Kramer, M.S., Tah Y. Chen, M.D., Joginder N. Bhayana,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationSmall cell lung cancer (SCLC), which represents 20%
ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationLung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09
Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationCarcinoma of the Lung in Women
Carcinoma of the Lung in Marvin M. Kirsh, M.D., Jeanne Tashian, M.A., and Herbert Sloan, M.D. ABSTRACT The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph
More informationIn non small cell lung cancer, metastasis to lymph nodes, the N factor, is
Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationFifteen-year follow-up of all patients in a study of
Br. J. Cancer (1985), 52, 867-873 Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma D.J. Girling, H. Stott, R.J. Stephens & W. Fox Medical Research
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationVATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS
VATS Metastasectomy Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute Disclosures Speaking & Education:
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationImpact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer
Impact of Radical Systematic Mediastinal Lymphadenectomy on Tumor Staging in Lung Cancer Jakob R. Izbicki, MD, Bernward Passlick, MD, Ortrud Karg, MD, Christian Bloechle, MD, Klaus Pantel, MD, Wolfram
More informationThere have been many attempts to develop effective
Postoperative Chemotherapy for Non-Small-Cell Lung Cancer* E. Carmack Holmes, M.D. The Lung Cancer Study Group has performed a number of postoperative adjuvant trials in patients with resectable DOD-small-ceO
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationM expected to arise in 1.6% to 3.0% of all patients. Multiple Primary Lung Carcinomas: Prognosis and Treatment
Multiple Primary Lung Carcinomas: Prognosis and Treatment Todd K. Rosengart, MD, Nael Martini, MD, Pierre Ghosn, MD, and Michael Burt, MD, PhD Thoracic Service, Department of Surgery, Memorial-Sloan Kettering
More informationIncidence of local recurrence and second primary tumors in resected stage I lung cancer
Incidence of local recurrence and second primary tumors in resected stage I lung cancer From 1973 to 1985, 598 patients underwent resection for stage I non-small-cell lung cancer. There were 291 T1 lesions
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationSurgical Treatment for Pulmonary Me. Tsunehisa; Kugimiya, Toshiyasu. Citation Acta medica Nagasakiensia. 1983, 28
NAOSITE: Nagasaki University's Ac Title Author(s) Surgical Treatment for Pulmonary Me Ayabe, Hiroyoshi; Tomita, Masao; Na Katsunobu; Nakao, Susumu; Eguchi, M Tsunehisa; Kugimiya, Toshiyasu Citation Acta
More informationThirty years of surgery for carcinoma of the bronchus
Thorax 1983;38:428-432 Thirty years of surgery for carcinoma of the bronchus JR BELCHER From the London Chest and Middlesex Hospitals, London ABSTRACr A study has been made of 8781 patients with bronchial
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationAggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn
Aggressive Slurgical Management of Testicular Carcinoma Metastatic to Lungs and Mediastinurn Isadore Mandelbaum, M.D., Stephen D. Williams, M.D., and Lawrence H. Einhorn, M.D. ABSTRACT During the past
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationThe Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer
The Importance of One-Stage Median Stemotomy and Retroperitoneal Node Dissection in Disseminated Testicular Cancer Isidore Mandelbaum, M.D., Peter B. Yaw, M.D., Lawrence H. Einhorn, M.D., Stephen D. Williams,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationMaster Class: Fundamentals of Lung Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationPostoperative Adjuvant Therapy for Stage II Non Small-Cell Lung Cancer
Postoperative Adjuvant Therapy for Stage II Non Small-Cell Lung Cancer Jong Ho Park, MD, Young Mog Shim, MD, Hee Jong Baek, MD, Mi-Sook Kim, MD, Du Hwan Choe, MD, Kyung-Ja Cho, MD, Choon-Taek Lee, MD,
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationDepartment of Otolaryngology, Kurume University School of Medicine, Kurume, Japan
THE KURUME MEDICAL JOURNAL Vol. 16, No. 3, 1969 PATHOLOGICAL STUDIES RELATING TO NEOPLASMS OF THE HYPOPHARYNX AND THE CERVICAL ESOPHAGUS IKUICHIRO HIROTO, YASUSHI NOMURA, KUSUO SUEYOSHI, SHIGENOBU MITSUHASHI,
More informationS promise of long-term survival for patients with nonsmall
Aggressive Surgical ntervention in N Non-Small Cell Cancer of the Lung Yoh Watanabe, MD, Junzo Shimizu, MD, Makoto Oda, MD, Yoshinobu Hayashi, MD, Shinichiro Watanabe, MD, Yasuhiko Tatsuzawa, MD, Takashi
More informationHodgkin s Disease of the Mediastinum
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 3 NUMBER 4 APRIL 1967 Hodgkin s Disease of the Mediastinum William A. Burke,
More informationStage 1 esophageal cancer survival rate
Stage 1 esophageal cancer survival rate Search Below are the five-year survival rates for esophageal cancer patients treated by SCCA compared to patients who were treated for esophageal. Stage I Esophageal
More informationR. F. Falkenstern-Ge, 1 S. Bode-Erdmann, 2 G. Ott, 2 M. Wohlleber, 1 and M. Kohlhäufl Introduction. 2. Histology
Case Reports in Oncological Medicine Volume 2013, Article ID 167585, 4 pages http://dx.doi.org/10.1155/2013/167585 Case Report Late Lung Metastasis of a Primary Eccrine Sweat Gland Carcinoma 10 Years after
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
More informationLung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.
Lung Case Scenario 1 A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density
More informationCarcinoma of the Lung: A Clinical Review
Carcinoma of the Lung: A Clinical Review R. Samuel Cromartie, 111, M.D., Edward F. Parker, M.D., James E. May, M.D., John S. Metcalf, M.D., and David M. Bartles, M.S. ABSTRACT Records of 702 patients with
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationTraditional Approaches to Treating NSCLC, Part 2: Neoadjuvant Combined Modality, Locally Advanced, and Metastatic NSCLC
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationLung cancer is the leading cause of cancer-related death in many
General Thoracic Surgery Chiu et al Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non small cell lung cancer patients: Preliminary report Chao-Hua Chiu, MD a,d Ming-Sheng
More informationSegmentectomy versus lobectomy in patients with stage I pulmonary carcinoma
Segmentectomy versus lobectomy in patients with stage pulmonary carcinoma Five-year survival and patterns of intrathoracic recurrence One hundred seventy-three patients with stage (Tl NO, T2 NO) non-small-cell
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationPrimary Tumors of Ribs
Primary Tumors of Ribs Frank E. Schmidt, M.D., and Max J. Trummer, Capt, MC, USN ABSTRACT An analysis of 50 consecutive patients with primary rib tumors operated on at the U.S. Naval Hospital, San Diego,
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationLymph Node MetastasG Tsuguo Naruke, M.D., Tomoyuki Goya, M.D., Ryosuke Tsuchiya, M.D., and Keiichi Suemasu, M.D.
ORIGINAL ARTICLES The Importance of Surgery to Non-Small Cell Carcinoma of Lung with Mediastinal Lymph Node MetastasG Tsuguo Naruke, M.D., Tomoyuki Goya, M.D., Ryosuke Tsuchiya, M.D., and Keiichi Suemasu,
More informationStaging of lung cancer provides a common language
The 1997 International Staging System for Non-Small Cell Lung Cancer* Have All the Issues Been Addressed? Swan S. Leong, MD; Caio M. Rocha Lima, MD; Carol A. Sherman, MD; and Mark R. Green, MD The International
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationEXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY
EXTENDED SLEEVE LOBECTOMY FOR LUNG CANCER: THE AVOIDANCE OF PNEUMONECTOMY Morihito Okada, MD Noriaki Tsubota, MD Masahiro Yoshimura, MD Yoshifumi Miyamoto, MD Hidehito Matsuoka, MD, Shinsuke Satake, MD
More informationVOLUME 19 NUMBER 2 * FEBRUARY 1975
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 9 NUMBER 2 * FEBRUARY 975 Medias tinoscopy Its Application in Central Versus
More informationL cancer-related deaths in Japan. The number of patients
Extended Resection of the Left Atrium, Great Vessels, or Both for Lung Cancer Ryosuke Tsuchiya, MD, Hisao Asamura, MD, Haruhiko Kondo, MD, Tomoyuki Goya, MD, and Tsuguo Naruke, MD Division of Thoracic
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationInterstitial Irradiation for Unresectable Carcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 20 NUMBER 5 NOVEMBER 1975 Interstitial Irradiation for Unresectable Carcinoma
More informationMETASTATIC PATTERN IN ADENOCARCINOMA OF THE LUNG
METASTATIC PATTERN IN ADENOCARCINOMA OF THE LUNG An autopsy study from a cohort of 137 consecutive patients with complete resection A cohort of 137 patients with completely resected stage I or II adenocarcinoma
More informationACRIN NLST 6654 Primary Lung Cancer. F1/F2 Interval: to (mm-dd-yyyy) 1. Date of diagnosis: (mm-dd-yyyy)
No. F1/F2 Interval: - - 20 to - - 20 (mm-dd-yyyy) 1. Date of diagnosis: - - 20 (mm-dd-yyyy) 2. Samples recorded: ZP Number S-Number 1) 2) 3) 4) (Refer to Form PX, Column 1. In the rare instance of a diagnosis
More informationI ing therapy, the most commonly used index
WHEN MAY ENDOMETRIAL CANCER BE CONSIDERED CURED? RICHARD R. MONSON, MD,* BRIAN MACMAHON, &ID,* AND JAMES H. AUSTIN, MD+ To assess when a woman may be considered cured following treatment for endometrial
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More information